Malignant Neoplasm

Oncology
6
Pipeline Programs
3
Companies
24
Clinical Trials
8 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
1100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
PALONOSETRON HYDROCHLORIDEApproved
palonosetron hydrochloride
Unknown Company
intravenous2018

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
3 programs
1
Palonosetron HydrochloridePhase 32 trials
Best PracticeN/A4 trials
Biospecimen CollectionN/A5 trials
Active Trials
NCT04549571Active Not Recruiting543Est. Jan 2027
NCT04379570Active Not Recruiting1,167Est. Aug 2026
NCT03857620Active Not Recruiting325Est. Oct 2025
+8 more trials
Knight Therapeutics
Knight TherapeuticsQC - Montréal
2 programs
1
1
NetupitantPhase 21 trial
Quality-of-Life AssessmentPhase 11 trial
Active Trials
NCT03677531Completed6Est. Sep 2019
NCT03097588Completed43Est. Mar 2020
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
Patritumab DeruxtecanPhase 1/2ADC
MK-4716Phase 11 trial
Active Trials
NCT07247110Recruiting250Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBest Practice
Alliance PharmaceuticalsPalonosetron Hydrochloride
Alliance PharmaceuticalsBest Practice
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Alliance PharmaceuticalsBiospecimen Collection
Knight TherapeuticsNetupitant
Alliance PharmaceuticalsPalonosetron Hydrochloride
Alliance PharmaceuticalsBiospecimen Collection

Showing 15 of 24 trials with date data

Clinical Trials (24)

Total enrollment: 14,210 patients across 24 trials

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Start: Jan 2026Est. completion: Sep 2038466 patients
Phase 3Not Yet Recruiting

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Start: Dec 2025Est. completion: May 20391,260 patients
Phase 3Recruiting

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Start: Oct 2025Est. completion: Sep 20341,524 patients
Phase 3Not Yet Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Start: Sep 2025Est. completion: Mar 20371,524 patients
Phase 3Recruiting

Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial

Start: Feb 2025Est. completion: Nov 20311,156 patients
Phase 3Suspended

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Start: Jun 2023Est. completion: May 20331,295 patients
Phase 3Recruiting

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Start: Feb 2021Est. completion: Aug 20261,167 patients
Phase 3Active Not Recruiting
NCT03578081Alliance PharmaceuticalsPalonosetron Hydrochloride

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Start: Nov 2018Est. completion: May 2023690 patients
Phase 3Completed

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

Start: Oct 2017Est. completion: Nov 2020158 patients
Phase 3Completed

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Start: Aug 2024Est. completion: Dec 202910 patients
Phase 2/3Active Not Recruiting

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Start: Aug 2023Est. completion: Jun 20341 patients
Phase 2/3Active Not Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Start: Feb 2025Est. completion: Oct 2034474 patients
Phase 2Recruiting

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Start: Apr 2017Est. completion: Mar 202043 patients
Phase 2Completed
NCT00903396Alliance PharmaceuticalsPalonosetron Hydrochloride

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Start: Sep 2009Est. completion: May 20137 patients
Phase 2Terminated

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Start: Jan 2023Est. completion: Jul 20250
Phase 1/2Withdrawn

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Start: Dec 2025Est. completion: Dec 2030250 patients
Phase 1Recruiting
NCT03677531Knight TherapeuticsQuality-of-Life Assessment

Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy

Start: May 2018Est. completion: Sep 20196 patients
Phase 1Completed

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Start: Aug 2022Est. completion: Feb 20272,000 patients
N/ARecruiting

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

Start: Mar 2022Est. completion: Dec 20301,001 patients
N/ARecruiting

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

Start: Feb 2021Est. completion: Jan 2027543 patients
N/AActive Not Recruiting

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Start: Mar 2020Est. completion: Oct 2026240 patients
N/ARecruiting

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

Start: Jul 2019Est. completion: Oct 2025325 patients
N/AActive Not Recruiting

Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

Start: Feb 2019Est. completion: Jul 202218 patients
N/ATerminated

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

Start: Nov 2018Est. completion: Dec 202252 patients
N/ATerminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
8 actively recruiting trials targeting 14,210 patients
3 companies competing in this space